Rob Maloney: Normalcy Is Not A Small Thing In Rare Disease
Rob Maloney, Chief Executive Officer of Hemophilia of Georgia, shared on LinkedIn:
”I’ve come to believe that one of the most powerful forms of care we offer isn’t a procedure or a prescription.
It’s belonging.
That’s why our camp matters so much.
To an outsider, camp can look like a nice program. Something optional. Something ‘extra.’
For many kids with hemophilia or bleeding disorders, it’s the first time in their life they’re in a place where they don’t feel different.
They see other kids who understand infusion.
They watch older campers who are confident and capable.
They realize there are adults living full lives with the same condition.
And something shifts internally.
They stop feeling like the exception. They stop feeling like the explanation.
Camp creates normalcy. And normalcy is not a small thing in rare disease.
It helps a child imagine a future that isn’t defined only by caution and limitation.
It gives parents a glimpse of what’s possible. It builds relationships that last far beyond a week in the summer.
Medicine keeps people alive.
Community helps them live well.
That’s why we protect it. That’s why we invest in it.
That’s why we keep showing up for it.”
Stay updated with Hemostasis Today.
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads
-
Aug 30, 2026, 16:18Tushar Namdeo: Platelets in Different Diseases
-
Aug 30, 2026, 16:16Fatima Zafar: Anaemia – Why This “Common” Condition Should Never Be Ignored
-
Aug 30, 2026, 16:13Umeshkumar C.: Evaluating Scoring Systems and Biomarkers for DIC in Critically Ill Patients